News|Articles|October 22, 2026

VitaK-CAC Study: Raising the Standard of Cardiovascular Health with MenaQ7® (Oct 2026)

This executive summary reviews the VitaK-CAC trial, which tested whether daily MK-7 supplementation could slow coronary artery calcification in adults with symptomatic coronary artery disease. Lacey Hall, MS, of Gnosis by Lesaffre covers the vitamin K2 biology behind the study, its 2-year results with MenaQ7®, and what the findings mean for formulators.


Related to this article